Investment bank ROTH Capital Partners LLC has further expanded its healthcare platform across investment banking, institutional sales, and equity research with the addition of Jack Terranova, Noah Huehnergarth, and Max Masucci.
Jack Terranova joins ROTH as managing director, healthcare investment banking, bringing more than 15 years of experience advising healthcare companies on capital markets, mergers and acquisitions, and strategic growth initiatives.
Noah Huehnergarth joins as executive director, institutional sales, enhancing the firm’s healthcare and growth-sector equities distribution capabilities. His prior experience includes directing and commercializing life sciences-dedicated equities platforms, while supporting capital markets transactions for emerging public companies.
Max Masucci has been appointed as managing director and senior research analyst leading coverage of the life science and diagnostic tools sector. He previously led highly ranked equity research franchises covering life science tools, diagnostics, and bioprocessing companies, earning industry recognition for thematic research and investor engagement.
In a statement, Aaron Gurewitz, co-CEO and head of investment banking at ROTH, commented, “A strong healthcare platform requires deep expertise across banking, sales, and research. The additions of Jack, Noah, and Max reflect our continued focus on building integrated, sector-specific teams that can deliver differentiated insights, capital markets execution, and investor connectivity for our healthcare clients.”
